查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1933313

全球抗病毒药物市场：市场规模、占有率、成长率、产业分析、依类型、应用和地区划分的考察、未来预测（2026-2034）

Antiviral Drugs Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 130 Pages | 商品交期: 请询问到货日

价格

抗病毒药物市场成长因素

预计全球抗病毒药物市场在预测期内将稳定成长。市场规模2025年达到423.4亿美元，2026年达到442.1亿美元，2034年将成长至543.7亿美元。这意味着2026年至2034年的年复合成长率（CAGR）为3.64%。北美地区占据市场主导地位，到2025年达到38.78%的市场占有率，这主要归功于该地区拥有众多大型製药公司、HIV等病毒感染的高发生率以及美国食品药品监督管理局（FDA）批准的多种药物。

病毒是由RNA或DNA组成，外层包裹着蛋白质外壳的感染性颗粒，能够感染人类细胞并引起病毒性疾病。病毒感染是严重的公共卫生问题，会导致显着的发病率和死亡率。抗病毒药物的作用机转是抑制病毒复製或恢復宿主细胞的正常功能。目前已知有超过1000种病毒感染人类，约占人类传染病的60%，因此对有效抗病毒治疗的需求仍然很高。然而，病毒的快速复製和缺乏快速诊断试剂给药物研发带来了挑战。

市场驱动因素

该市场的主要驱动因素是爱滋病毒和流感在全球范围内的蔓延。根据世界卫生组织统计，截至2018年，全球约有3,790万人感染爱滋病毒，77万人死于此病。加强爱滋病毒监测和改进诊断工具扩大符合抗病毒疗法条件的患者群体。同样，流感快速诊断也促进了抗病毒药物需求的成长。

重磅疗法的推出进一步加速了市场成长。诸如Biktarvy（Gilead Sciences）和Trumeq（GlaxoSmithKline）等药物彻底改变了抗逆转录病毒疗法，提高了患者的治疗效果和依从性。 Biktarvy于2024年2月获批，主要针对接受抗逆转录病毒疗法的约2100万HIV感染者，能够显着增强免疫系统。

市场限制因子

抗病毒药物价格昂贵，且在发展中国家取得途径有限，这些都阻碍了其广泛应用。此外，抗药性病毒株的出现也要求持续进行研发工作，以开发下一代疗法。

市场区隔

依药物类别划分：

  • 到2026年，复方製剂将占据63.32%的市场占有率，主要得益于Genvoya、Mavyret和Triumeq等品牌。
  • 由于Tivicay和Isentress等高效且耐受性良好的药物，整合酶抑制剂预计将实现成长。
  • 其他类别包括蛋白酶抑制剂、聚合酶抑制剂、逆转录酶抑制剂和其他药物。

依疾病划分：

  • 到2026年，HIV将占据82.04%的市场占有率，由于其高盛行率和有利的健保偿付政策，HIV将继续保持领先地位。
  • 其他适应症包括肝炎、流感、疱疹、轮状病毒和其他病毒感染。政府参与爱滋病防治宣传和预防计画也促进了市场成长。

依通路划分：

  • 由于政府支持、有利的偿付制度和完善的供应链网路，医院药房占据市场主导地位。
  • 到2026年，零售药局将占据47.66%的市场占有率，这得益于非处方药和仿製抗病毒药物的普及。
  • 由于线上通路的便利性和可近性提高，预计线上通路将实现显着成长。

区域分析

北美：到2025年，营收达到164.2亿美元，主要受美国市场驱动。爱滋病毒感染率高、实力雄厚的製药公司以及重磅疗法的核准是推动美国市场成长的关键因素。预计到2026年，美国市场规模将达到142.2亿美元。

亚太地区：由于印度和日本医药基础设施的改善、病毒疫情的频繁爆发以及政府在疾病控制方面的积极参与，预计该地区将呈现最高的年复合成长率。到2026年，日本市场规模预计将达到18.6亿美元，中国市场规模将达27.2亿美元，印度市场规模将达25.7亿美元。

欧洲：有利的偿付制度、新产品的推出以及政府的积极支持推动了市场成长。预计到2026年，英国和德国市场规模将分别达到 17.1亿美元和 27.1亿美元。

拉丁美洲、中东和非洲：预计成长将受到医疗基础设施改善、宣传活动以及政府主导的目的是满足有效抗病毒疗法未满足需求的举措的推动。

目录

第1章 引言

第2章 执行摘要

第3章 市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机会

第4章 主要考察

  • 主要行业趋势
  • 主要趋势：併购等
  • 主要国家的监管和偿付情况
  • 主要国家主要病毒性疾病的流行情况（2025年）
  • 新产品上市

第5章 全球抗病毒药物市场分析：洞察与预测（2021-2034）

  • 关键分析/摘要
  • 市场分析、洞察与预测：依疾病分类
    • 肝炎
    • 人类免疫缺乏病毒（HIV）
    • 流感
    • 其他
  • 市场分析、洞察与预测：依药物类别
    • 整合酶抑制剂
    • 聚合酶抑制剂
    • 蛋白酶/转录酶抑制剂
    • 复方药物
    • 逆转录酶抑制剂
    • 其他
  • 市场分析、洞察与预测：依通路
    • 医院药房
    • 零售药房
    • 线上渠道
  • 市场分析，洞察与预测：依地区划分
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

第6章 北美抗病毒药物市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 美国
    • 加拿大

第7章 欧洲抗病毒药物市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 英国
    • 德国
    • 法国
    • 西班牙
    • 义大利
    • 斯堪的纳维亚半岛
    • 其他地区欧洲

第8章 亚太地区抗病毒药物市场分析、洞察与预测（2021-2034）

  • 依国家划分
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 东南亚
    • 亚太其他地区

第9章 拉丁美洲抗病毒药物市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区

第10章 中东与非洲抗病毒药物市场分析：洞察与预测（2021-2034）

  • 依国家划分
    • GCC国家
    • 南非
    • 中东和非洲其他地区

第11章 竞争分析

  • 主要行业趋势
  • 全球市场占有率分析（2018）
  • 竞争概览
  • 主要公司比较分析
  • 公司简介
  • Gilead Sciences
  • GlaxoSmithKline
  • Abbvie, Inc.
  • Merck &Co., Inc.
  • Bristol-Myers Squibb Company
  • Janssen Pharmaceuticals, Inc.
  • Mylan N.V.
  • Novartis AG

第12章 策略建议

Product Code: FBI102190

Growth Factors of antiviral drugs Market

The global antiviral drugs market is expected to experience steady growth over the forecast period. In 2025, the market was valued at USD 42.34 billion, projected to reach USD 44.21 billion in 2026, and expand to USD 54.37 billion by 2034, representing a CAGR of 3.64% from 2026-2034. North America dominated the market in 2025 with a 38.78% share, attributed to the presence of leading pharmaceutical companies, high prevalence of viral infections such as HIV, and multiple USFDA drug approvals.

Viruses are infectious particles containing RNA or DNA enclosed in a protein coat, capable of infecting human cells and causing viral diseases. Viral infections are a significant public health concern, responsible for considerable morbidity and mortality. Antiviral drugs work by inhibiting viral replication or restoring the normal function of host cells. With over a thousand viruses infecting humans and accounting for approximately 60% of human infections, the demand for effective antiviral therapies remains high. However, rapid virus replication and lack of quick diagnostic reagents present challenges in drug development.

Market Drivers

The market is primarily driven by the rising prevalence of HIV and influenza globally. According to WHO, approximately 37.9 million people were living with HIV in 2018, with 770,000 deaths attributed to the disease. Enhanced HIV surveillance and improved diagnostic tools have expanded the patient pool for antiretroviral therapies. Similarly, the rapid diagnosis of influenza has increased the demand for antiviral drugs.

The introduction of blockbuster therapeutics has further fueled market growth. Drugs like Biktarvy (Gilead Sciences) and Triumeq (GlaxoSmithKline) have revolutionized antiretroviral therapy, improving patient outcomes and treatment adherence. Biktarvy, approved in February 2024, targets populations living with HIV, where approximately 21 million people receive antiretroviral therapy, significantly strengthening immune systems.

Market Restraints

High costs of antiviral medications and limited access in developing countries pose barriers to widespread adoption. Additionally, the emergence of resistant viral strains requires ongoing R&D to develop next-generation therapies.

Market Segmentation

By Drug Class:

  • Combination drugs dominate with a 63.32% share in 2026, driven by brands like Genvoya, Mavyret, and Triumeq.
  • Integrase inhibitors are projected to expand due to potent drugs like Tivicay and Isentress, favored for high efficacy and tolerability.
  • Other classes include protease inhibitors, polymerase inhibitors, reverse transcriptase inhibitors, and miscellaneous agents.

By Disease Indication:

  • HIV dominates with an 82.04% share in 2026, owing to its high prevalence and supportive reimbursement policies.
  • Other indications include hepatitis, influenza, herpes, rotavirus, and other viral infections. Government participation in HIV awareness and preventive programs also supports market growth.

By Distribution Channel:

  • Hospital pharmacies dominate due to government support, favorable reimbursement, and organized supply networks.
  • Retail pharmacies hold a 47.66% share in 2026, supported by OTC and generic antiviral availability.
  • Online channels are projected to grow significantly due to increased accessibility and convenience.

Regional Analysis

North America: Revenue of USD 16.42 billion in 2025, led by U.S. market, driven by HIV prevalence, strong pharmaceutical presence, and approvals of blockbuster therapies. U.S. market projected to reach USD 14.22 billion by 2026.

Asia Pacific: Expected to show the highest CAGR, driven by improved pharmaceutical infrastructure in India and Japan, frequent viral outbreaks, and government participation in disease management. Markets in Japan, China, and India are projected at USD 1.86 billion, USD 2.72 billion, and USD 2.57 billion by 2026, respectively.

Europe: Market growth supported by favorable reimbursement, new product launches, and active government support. UK and Germany projected at USD 1.71 billion and USD 2.71 billion by 2026, respectively.

Latin America & Middle East/Africa: Growth driven by improved healthcare infrastructure, awareness campaigns, and government initiatives to address unmet needs for effective antiviral therapies.

Competitive Landscape

Key players include Gilead Sciences, GlaxoSmithKline, AbbVie, Merck & Co., Bristol-Myers Squibb, Janssen Pharmaceuticals, Mylan, and Novartis.

Notable Developments:

  • July 2021: Vaxart, Inc. licensed Vapendavir to Altesa Biosciences for clinical-stage antiviral development.
  • June 2021: Pardes Biosciences and FS Development merged to advance oral antivirals against SARS-CoV-2.
  • March 2021: Pfizer initiated Phase 1 study for oral protease inhibitor PF-07321332 targeting SARS-CoV-2.
  • January 2021: ViiV Healthcare received FDA approval for Cabenuva, reducing HIV treatment dosing from 365 to 12 days annually.

Conclusion

The antiviral drugs market is projected to grow from USD 42.34 billion in 2025 to USD 54.37 billion by 2034, at a CAGR of 3.64%. Market growth is primarily driven by the high prevalence of HIV and influenza, introduction of blockbuster drugs, and increasing government support for public health initiatives. Hospital pharmacies continue to dominate distribution, while emerging online channels enhance accessibility. North America maintains the largest market share, while Asia Pacific is expected to witness the highest growth due to expanding healthcare infrastructure and rising viral disease burden. The presence of established pharmaceutical players and robust pipeline developments are anticipated to shape the competitive landscape, ensuring continued growth in antiviral therapeutics worldwide.

Segmentation By Drug Class

  • Protease Inhibitors
  • Polymerase Inhibitors
  • Integrase Inhibitors
  • Reverse Transcriptase Inhibitors
  • Combination Drugs
  • Others

By Disease Indication

  • Hepatitis
  • Human Immunodeficiency Virus (HIV)
  • Influenza
  • Others

By Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Channel

By Geography

  • North America (U.S. and Canada)
  • Europe (U.K., Germany, France, Italy, Spain, Scandinavia, and Rest of Europe)
  • Asia Pacific (Japan, China, India, Australia, Southeast Asia, and Rest of Asia Pacific)
  • Latin America (Brazil, Mexico, and Rest of Latin America)
  • Middle East and Africa (South Africa, GCC, and Rest of Middle East & Africa)

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities

4. Key Insights

  • 4.1. Key Industry Trends
  • 4.2. Recent industry developments such as mergers & acquisitions
  • 4.3. regulatory and reimbursement scenario for key countries
  • 4.4. Prevalence of Key viral diseases, in major countries, 2025
  • 4.5. New Product Launches

5. Global Antiviral Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Key Findings / Summary
  • 5.2. Market Analysis, Insights and Forecast - By Disease Indication
    • 5.2.1. Hepatitis
    • 5.2.2. Human Immunodeficiency Virus (HIV)
    • 5.2.3. Influenza
    • 5.2.4. Others
  • 5.3. Market Analysis, Insights and Forecast - By Drug Class
    • 5.3.1. Integrase Inhibitors
    • 5.3.2. Polymerase Inhibitors
    • 5.3.3. Protease Inhibitors
    • 5.3.4. Combination Drugs
    • 5.3.5. Reverse Transcriptase Inhibitors
    • 5.3.6. Others
  • 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.4.1. Hospital Pharmacy
    • 5.4.2. Retail Pharmacy
    • 5.4.3. Online Channel
  • 5.5. Market Analysis, Insights and Forecast - By Region
    • 5.5.1. North America
    • 5.5.2. Europe
    • 5.5.3. Asia Pacific
    • 5.5.4. Latin America
    • 5.5.5. Middle East & Africa

6. North America Antiviral Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Key Findings / Summary
  • 6.2. Market Analysis - By Disease Indication
    • 6.2.1. Hepatitis
    • 6.2.2. Human Immunodeficiency Virus (HIV)
    • 6.2.3. Influenza
    • 6.2.4. Others
  • 6.3. Market Analysis - By Drug Class
    • 6.3.1. Integrase Inhibitors
    • 6.3.2. Polymerase Inhibitors
    • 6.3.3. Protease Inhibitors
    • 6.3.4. Combination Drugs
    • 6.3.5. Reverse Transcriptase Inhibitors
    • 6.3.6. Others
  • 6.4. Market Analysis - By Distribution Channel
    • 6.4.1. Hospital Pharmacy
    • 6.4.2. Retail Pharmacy
    • 6.4.3. Online Channel
  • 6.5. Market Analysis - By Country
    • 6.5.1. U.S.
    • 6.5.2. Canada

7. Europe Antiviral Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Key Findings / Summary
  • 7.2. Market Analysis - By Disease Indication
    • 7.2.1. Hepatitis
    • 7.2.2. Human Immunodeficiency Virus (HIV)
    • 7.2.3. Influenza
    • 7.2.4. Others
  • 7.3. Market Analysis - By Drug Class
    • 7.3.1. Integrase Inhibitors
    • 7.3.2. Polymerase Inhibitors
    • 7.3.3. Protease Inhibitors
    • 7.3.4. Combination Drugs
    • 7.3.5. Reverse Transcriptase Inhibitors
    • 7.3.6. Others
  • 7.4. Market Analysis - By Distribution Channel
    • 7.4.1. Hospital Pharmacy
    • 7.4.2. Retail Pharmacy
    • 7.4.3. Online Channel
  • 7.5. Market Analysis - By Country/Sub-region
    • 7.5.1. U.K.
    • 7.5.2. Germany
    • 7.5.3. France
    • 7.5.4. Spain
    • 7.5.5. Italy
    • 7.5.6. Scandinavia
    • 7.5.7. Rest of Europe

8. Asia Pacific Antiviral Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Key Findings / Summary
  • 8.2. Market Analysis - By Disease Indication
    • 8.2.1. Hepatitis
    • 8.2.2. Human Immunodeficiency Virus (HIV)
    • 8.2.3. Influenza
    • 8.2.4. Others
  • 8.3. Market Analysis - By Drug Class
    • 8.3.1. Integrase Inhibitors
    • 8.3.2. Polymerase Inhibitors
    • 8.3.3. Protease Inhibitors
    • 8.3.4. Combination Drugs
    • 8.3.5. Reverse Transcriptase Inhibitors
    • 8.3.6. Others
  • 8.4. Market Analysis - By Distribution Channel
    • 8.4.1. Hospital Pharmacy
    • 8.4.2. Retail Pharmacy
    • 8.4.3. Online Channel
  • 8.5. Market Analysis - By Country/Sub-region
    • 8.5.1. Japan
    • 8.5.2. China
    • 8.5.3. India
    • 8.5.4. Australia
    • 8.5.5. Southeast Asia
    • 8.5.6. Rest of Asia Pacific

9. Latin America Antiviral Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Key Findings / Summary
  • 9.2. Market Analysis - By Disease Indication
    • 9.2.1. Hepatitis
    • 9.2.2. Human Immunodeficiency Virus (HIV)
    • 9.2.3. Influenza
    • 9.2.4. Others
  • 9.3. Market Analysis - By Drug Class
    • 9.3.1. Integrase Inhibitors
    • 9.3.2. Polymerase Inhibitors
    • 9.3.3. Protease Inhibitors
    • 9.3.4. Combination Drugs
    • 9.3.5. Reverse Transcriptase Inhibitors
    • 9.3.6. Others
  • 9.4. Market Analysis - By Distribution Channel
    • 9.4.1. Hospital Pharmacy
    • 9.4.2. Retail Pharmacy
    • 9.4.3. Online Channel
  • 9.5. Market Analysis - By Country/Sub-region
    • 9.5.1. Brazil
    • 9.5.2. Mexico
    • 9.5.3. Rest of Latin America

10. Middle East & Africa Antiviral Drugs Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Key Findings / Summary
  • 10.2. Market Analysis - By Disease Indication
    • 10.2.1. Hepatitis
    • 10.2.2. Human Immunodeficiency Virus (HIV)
    • 10.2.3. Influenza
    • 10.2.4. Others
  • 10.3. Market Analysis - By Drug Class
    • 10.3.1. Integrase Inhibitors
    • 10.3.2. Polymerase Inhibitors
    • 10.3.3. Protease Inhibitors
    • 10.3.4. Combination Drugs
    • 10.3.5. Reverse Transcriptase Inhibitors
    • 10.3.6. Others
  • 10.4. Market Analysis - By Distribution Channel
    • 10.4.1. Hospital Pharmacy
    • 10.4.2. Retail Pharmacy
    • 10.4.3. Online Channel
  • 10.5. Market Analysis - By Country/Sub-region
    • 10.5.1. GCC Countries
    • 10.5.2. South Africa
    • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Key Industry Developments
  • 11.2. Global Market Share Analysis (2018)
  • 11.3. Competition Dashboard
  • 11.4. Comparative Analysis - Major Players
  • 11.5. Company Profiles (Overview, Products & services, SWOT analysis, Recent developments, strategies, financials (based on availability))
    • 11.5.1. Gilead Sciences
      • 11.5.1.1. Overview,
      • 11.5.1.2. Products & services,
      • 11.5.1.3. SWOT analysis,
      • 11.5.1.4. Recent developments,
      • 11.5.1.5. strategies,
      • 11.5.1.6. financials (based on availability)
    • 11.5.2. GlaxoSmithKline
      • 11.5.2.1. Overview,
      • 11.5.2.2. Products & services,
      • 11.5.2.3. SWOT analysis,
      • 11.5.2.4. Recent developments,
      • 11.5.2.5. strategies,
      • 11.5.2.6. financials (based on availability)
    • 11.5.3. Abbvie, Inc.
      • 11.5.3.1. Overview,
      • 11.5.3.2. Products & services,
      • 11.5.3.3. SWOT analysis,
      • 11.5.3.4. Recent developments,
      • 11.5.3.5. strategies,
      • 11.5.3.6. financials (based on availability)
    • 11.5.4. Merck & Co., Inc.
      • 11.5.4.1. Overview,
      • 11.5.4.2. Products & services,
      • 11.5.4.3. SWOT analysis,
      • 11.5.4.4. Recent developments,
      • 11.5.4.5. strategies,
      • 11.5.4.6. financials (based on availability)
    • 11.5.5. Bristol-Myers Squibb Company
      • 11.5.5.1. Overview,
      • 11.5.5.2. Products & services,
      • 11.5.5.3. SWOT analysis,
      • 11.5.5.4. Recent developments,
      • 11.5.5.5. strategies,
      • 11.5.5.6. financials (based on availability)
    • 11.5.6. Janssen Pharmaceuticals, Inc.
      • 11.5.6.1. Overview,
      • 11.5.6.2. Products & services,
      • 11.5.6.3. SWOT analysis,
      • 11.5.6.4. Recent developments,
      • 11.5.6.5. strategies,
      • 11.5.6.6. financials (based on availability)
    • 11.5.7. Mylan N.V.
      • 11.5.7.1. Overview,
      • 11.5.7.2. Products & services,
      • 11.5.7.3. SWOT analysis,
      • 11.5.7.4. Recent developments,
      • 11.5.7.5. strategies,
      • 11.5.7.6. financials (based on availability)
    • 11.5.8. Novartis AG
      • 11.5.8.1. Overview,
      • 11.5.8.2. Products & services,
      • 11.5.8.3. SWOT analysis,
      • 11.5.8.4. Recent developments,
      • 11.5.8.5. strategies,
      • 11.5.8.6. financials (based on availability)

12. Strategic Recommendations

List of Tables

  • Table 1: Global Antiviral Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2015-2034
  • Table 2: Global Antiviral Drugs Market Revenue (US$ Mn) Forecast, by Disease Indication, 2015-2034
  • Table 3: Global Antiviral Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2015-2034
  • Table 4: Global Antiviral Drugs Market Revenue (US$ Mn) Forecast, by Region, 2021-2034
  • Table 5: North America Antiviral Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2021-2034
  • Table 6: North America Antiviral Drugs Market Revenue (US$ Mn) Forecast, by Disease Indication, 2021-2034
  • Table 7: North America Antiviral Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 8: North America Antiviral Drugs Market Revenue (US$ Mn) Forecast, By Country, 2021-2034
  • Table 9: Europe Antiviral Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2021-2034
  • Table 10: Europe Antiviral Drugs Market Revenue (US$ Mn) Forecast, by Disease Indication, 2021-2034
  • Table 11: Europe Antiviral Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 12: Europe Antiviral Drugs Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 13: Asia Pacific Antiviral Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2021-2034
  • Table 14: Asia Pacific Antiviral Drugs Market Revenue (US$ Mn) Forecast, by Disease Indication, 2021-2034
  • Table 15: Asia Pacific Antiviral Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 16: Asia Pacific Antiviral Drugs Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 17: Latin America Antiviral Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2021-2034
  • Table 18: Latin America Antiviral Drugs Market Revenue (US$ Mn) Forecast, by Disease Indication, 2021-2034
  • Table 19: Latin America Antiviral Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 20: Latin America Antiviral Drugs Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Middle East & Africa Antiviral Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2021-2034
  • Table 22: Middle East & Africa Antiviral Drugs Market Revenue (US$ Mn) Forecast, by Disease Indication, 2021-2034
  • Table 23: Middle East & Africa Antiviral Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 24: Middle East & Africa Antiviral Drugs Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034

List of Figures

  • Table 1: Global Antiviral Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2015-2034
  • Table 2: Global Antiviral Drugs Market Revenue (US$ Mn) Forecast, by Disease Indication, 2015-2034
  • Table 3: Global Antiviral Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2015-2034
  • Table 4: Global Antiviral Drugs Market Revenue (US$ Mn) Forecast, by Region, 2021-2034
  • Table 5: North America Antiviral Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2021-2034
  • Table 6: North America Antiviral Drugs Market Revenue (US$ Mn) Forecast, by Disease Indication, 2021-2034
  • Table 7: North America Antiviral Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 8: North America Antiviral Drugs Market Revenue (US$ Mn) Forecast, By Country, 2021-2034
  • Table 9: Europe Antiviral Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2021-2034
  • Table 10: Europe Antiviral Drugs Market Revenue (US$ Mn) Forecast, by Disease Indication, 2021-2034
  • Table 11: Europe Antiviral Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 12: Europe Antiviral Drugs Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 13: Asia Pacific Antiviral Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2021-2034
  • Table 14: Asia Pacific Antiviral Drugs Market Revenue (US$ Mn) Forecast, by Disease Indication, 2021-2034
  • Table 15: Asia Pacific Antiviral Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 16: Asia Pacific Antiviral Drugs Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 17: Latin America Antiviral Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2021-2034
  • Table 18: Latin America Antiviral Drugs Market Revenue (US$ Mn) Forecast, by Disease Indication, 2021-2034
  • Table 19: Latin America Antiviral Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 20: Latin America Antiviral Drugs Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034
  • Table 21: Middle East & Africa Antiviral Drugs Market Revenue (US$ Mn) Forecast, by Drug Class, 2021-2034
  • Table 22: Middle East & Africa Antiviral Drugs Market Revenue (US$ Mn) Forecast, by Disease Indication, 2021-2034
  • Table 23: Middle East & Africa Antiviral Drugs Market Revenue (US$ Mn) Forecast, by Distribution Channel, 2021-2034
  • Table 24: Middle East & Africa Antiviral Drugs Market Revenue (US$ Mn) Forecast, By Country/ Sub-region, 2021-2034